Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct description

Phase of product development

23 evidence topics · 19 sources

Launch

No evidence found.

Commercial launch preparation
FDA orphan drug designation, November 2023
FieldQuoted record
Generic name“varegacestat”
Date designated“11/02/2023”
Orphan designation“Treatment of desmoid tumors”
Orphan designation status“Designated”
FDA orphan approval status“Not FDA Approved for Orphan Indication”
Sponsor“Immunome, Inc.”
Development history: acquisition by Immunome from Ayala Pharmaceuticals, March 2024